Advanced hepatocellular carcinoma is late-stage primary liver cancer (HCC) where disease is unresectable, metastatic, or otherwise not amenable to curative local therapy. It is commonly associated with underlying chronic liver disease and requires systemic treatment approaches.
Medivir's 2025 Annual Report highlights FDA Orphan Drug Designation for MIV-711 in Osteogenesis Imperfecta and promising fostrox liver cancer data showing 13.7-month median survival. The company raised SEK 196 million to fund Phase 2 studies for both programs and reported year-end cash of SEK 119.2 million.
Iterion Therapeutics has dosed the first patient in a phase 1/2 trial of its Wnt/β-catenin inhibitor tegavivint for metastatic colorectal cancer. The expansion builds on promising monotherapy activity observed in advanced hepatocellular carcinoma, targeting a pathway activated in over 90% of colorectal cancer patients.
DelveInsight pipeline reports reveal robust clinical development across three cancer indications, with 45+ companies advancing cutaneous squamous cell carcinoma therapies, 70+ companies developing liver cancer treatments, and multiple hepatocellular carcinoma candidates receiving FDA designations in 2025-2026.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07405086 |
Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study |
RECRUITING | PHASE4 |
| NCT07297654 |
First-Line Lenvatinib in Child-Pugh B Patients With HCC Unsuitable for Curative Treatment |
NOT_YET_RECRUITING | PHASE2 |
| NCT07227012 |
Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body. |
RECRUITING | PHASE1/PHASE2 |
| NCT07201064 |
A Study of SZ1003 Injection in Patients With Advanced Hepatocellular Carcinoma |
NOT_YET_RECRUITING | EARLY_PHASE1 |
| NCT07174570 |
Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer |
RECRUITING | PHASE2 |
| NCT07166406 |
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial |
RECRUITING | PHASE3 |
| NCT07042919 |
Zanzalintinib in Second Line and Beyond for the Treatment of Advanced Liver Cancer |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT06986785 |
A Study of BL-B01D1 Combined With Lenvatinib in Patients With Advanced Hepatocellular Carcinoma |
RECRUITING | PHASE2 |
| NCT06968195 |
Autologous CAR T Cells Targeting GPC3 (RPCAR01) for the Treatment of Advanced or Metastatic GPC3 Expressing Hepatocellular Carcinoma |
SUSPENDED | PHASE1 |
| NCT06811116 |
Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial |
RECRUITING | PHASE1/PHASE2 |
